Open AccessEffects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study)
Author(s) -
Joy N. Tsai,
Alexander V. Uihlein,
SherriAnn M. BurnettBowie,
Robert M. Neer,
Nicholas P. Derrico,
H. Lee,
Mary Bouxsein,
Benjamin Z. Leder
Publication year - 2016
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2016-1160
Subject(s) - teriparatide , tibia , bone mineral , denosumab , medicine , quantitative computed tomography , osteoporosis , cortical bone , urology , surgery , anatomy
In postmenopausal osteoporosis, combining denosumab and teriparatide increases hip and spine bone mineral density more than either monotherapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom